NeoGenomics is a diagnostics & research business based in the US. NeoGenomics shares (NEO) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $15.36 – a decrease of 6.51% over the previous week. NeoGenomics employs 2,100 staff and has a trailing 12-month revenue of around $644.1 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $15.36 |
|---|---|
| 52-week range | $12.77 - $21.22 |
| 50-day moving average | $14.69 |
| 200-day moving average | $14.86 |
| Wall St. target price | $20.91 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-0.59 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $15.36 from 2024-11-19
| 1 week (2024-11-14) | -2.72% |
|---|---|
| 1 month (2024-10-21) | 16.98% |
| 3 months (2024-08-21) | -6.51% |
| 6 months (2024-05-21) | 3.92% |
| 1 year (2023-11-21) | -19.92% |
|---|---|
| 2 years (2022-11-21) | 49.85% |
| 3 years (2021-11-19) | 40.03 |
| 5 years (2019-11-21) | 24.53 |
Valuing NeoGenomics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of NeoGenomics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
NeoGenomics's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 3.02. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into NeoGenomics's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
| Revenue TTM | $644.1 million |
|---|---|
| Gross profit TTM | $187.9 million |
| Return on assets TTM | -2.76% |
| Return on equity TTM | -8.38% |
| Profit margin | -12.07% |
| Book value | $7.09 |
| Market Capitalization | $2 billion |
TTM: trailing 12 months
We're not expecting NeoGenomics to pay a dividend over the next 12 months.
NeoGenomics's shares were split on a 1:100 basis on 15 April 2003 . So if you had owned 100 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your NeoGenomics shares – just the quantity. However, indirectly, the new 9900% higher share price could have impacted the market appetite for NeoGenomics shares which in turn could have impacted NeoGenomics's share price.
Over the last 12 months, NeoGenomics's shares have ranged in value from as little as $12.77 up to $21.22. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while NeoGenomics's is 1.183. This would suggest that NeoGenomics's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. NeoGenomics, Inc.
The $500 Axos Bank bonus is now expired, but you can still earn $50 per qualifying referral, plus up to $400 with a new business account.
Find out if Priority Plus Financial’s advertised loans are worth it or just a sales hook.
Where to get a holiday loan in 2024 and whether it makes sense for you.
Modak has no monthly fee, but it’s slim on features. Greenlight starts at $5.99 but is a value for big families.
Get the capital your business needs to grow with repayments that adapt to your revenue.
We’ve compared the best cash advance apps for quick cash — find the right one for your needs.
A review of Beyond Finance, a company that offers debt settlement and consolidation loans.
1. Make a budget 2. Create a savings plan 3. Automate savings 4. Pay yourself first 5. Use a high-yield account 6. Do a savings challenge…
To save $10K: 1. Automate savings 2. Invest 3. Budget 4. Open a high-yield savings account 5. Cut down on spending 6. Pay off debt…
A review of Arrowhead Advance, a tribal lender that charges interest rates up to 830% and has numerous bad reviews.